Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466631 | 0.91 | PTGDR2 (0.42) | PTGDR2PTGDRCYP2C9ALDH1A1 | |
| SCHEMBL1466409 | 0.91 | PTGDR2 (0.56) | PTGDR2PTGDRCYP2C9PTGIR | |
| SCHEMBL1467977 | 0.88 | PTGDR2 (0.62) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL1603176 | 0.86 | PTGDR2 (0.56) | PTGDR2PTGDRCYP2C9PTGIR | |
| SCHEMBL1466412 | 0.83 | PTGDR2 (0.51) | PTGDR2PTGDRCYP2C9 | |
| SCHEMBL1921782 | 0.82 | PTGDR2 (0.57) | PTGDR2PTGDRCYP2C9PTGIR | |
| SCHEMBL1465979 | 0.81 | PTGDR2 (0.46) | PTGDR2PTGDRCYP2C9ALDH1A1 | |
| SCHEMBL1422452 | 0.80 | PTGDR2 (0.52) | PTGDR2PTGDRCYP2C9PTGIR | |
| SCHEMBL1467731 | 0.80 | PTGDR2 (0.52) | PTGDR2PTGDRCYP2C9PTGIR | |
| SCHEMBL1599312 | 0.80 | PTGDR2 (0.56) | PTGDR2PTGDRCYP2C9PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | PTGDR2 39/4885PTGDR 60/4885CYP2C9 3588/4885 |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | FPR3, HRH2, HRH4 | PTGDR2 161/4885PTGDR 139/4885CYP2C9 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.